AstraZeneca (AZN.L) Osake Kurssi

AstraZeneca PLC is primarily active in the pharmaceutical and biotechnology industries.

AstraZeneca PLC's main competitors in the market include pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Novartis. These companies also operate in the healthcare sector and offer a wide range of prescription drugs, vaccines, and consumer health products. However, AstraZeneca PLC has carved a niche for itself with its innovative research and development initiatives, particularly in the field of oncology and respiratory diseases. Their commitment to addressing unmet medical needs differentiates them from competitors in the pharmaceutical industry.

AstraZeneca PLC is a renowned British-Swedish multinational pharmaceutical and biopharmaceutical company. Established in 1999 through a merger, AstraZeneca has a rich history dating back to the 19th century. The company specializes in innovative prescription medicines, biologics, and oncology therapies that improve the health and well-being of millions of people worldwide. AstraZeneca is dedicated to developing groundbreaking treatments for various therapeutic areas, including cardiovascular, respiratory, metabolic, and autoimmune diseases, as well as cancer. With a steadfast commitment to research and development, AstraZeneca continues to make significant contributions to the global healthcare industry, improving patients' lives and advancing medical science.

AstraZeneca PLC, a renowned pharmaceutical company, has achieved several significant milestones. Firstly, they have made remarkable advancements in the field of cancer treatment, particularly with drugs like Tagrisso and Lynparza, aiding patients worldwide. Secondly, AstraZeneca has developed lifesaving medications for chronic respiratory diseases, including Symbicort and Pulmicort, improving the quality of life for millions. Furthermore, AstraZeneca's COVID-19 vaccine, developed in collaboration with the University of Oxford, has played a pivotal role in combating the global pandemic. Their dedication to scientific innovation and commitment to global health has positioned AstraZeneca PLC as a prominent leader in the pharmaceutical industry.

AstraZeneca PLC is primarily present in multiple countries and regions across the globe. The company operates in the United States, United Kingdom, Sweden, France, Germany, China, Brazil, Canada, Japan, and many others. With a robust global footprint, AstraZeneca PLC's presence spans across North America, Europe, Asia-Pacific, Latin America, and the Middle East. As a renowned pharmaceutical company, AstraZeneca PLC delivers innovative medicines and healthcare solutions to enhance patient lives worldwide.

AstraZeneca PLC represents values of innovation, integrity, and patient-centricity in its corporate philosophy. As a leading global pharmaceutical company, AstraZeneca is dedicated to transforming the lives of patients through scientific advancements and breakthrough treatments. The company is committed to ethical business practices, ensuring transparency and accountability in all its operations. With a focus on collaboration and strategic partnerships, AstraZeneca aims to address unmet medical needs and improve healthcare worldwide. By combining cutting-edge research and a patient-first approach, AstraZeneca continues to pave the way for the development of innovative and life-saving medicines.

34 analyytikkoa arvioi tällä hetkellä AstraZeneca-osaketta: 28 suosittaa ostoa, 5 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat AstraZeneca-yhtiöltä 63,02 Mrd. USD liikevaihtoa ja 10,24 USD osakekohtaista tulosta.

AstraZeneca Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla AstraZeneca-osake noteerataan hintaan 146,88 EUR (165,11 USD).

AstraZeneca-osake (AZN.L) on listattuna 11 pörssissä, muun muassa: London (AZN.L), SIX (Zürich) (AZN.SW), XETRA (ZEG.DE), Frankfurt (ZEG.F), München (ZEG.MU), Düsseldorf (ZEG.DU), Hamburg (ZEG.HM), Stockholm (AZN.ST).

AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications in the fields of cancer, cardiovascular, respiratory, immunology, and infectious diseases. It was founded in 1999 by the merger of Astra AB and Zeneca Group plc. The company is headquartered in London, UK, and employs over 70,000 employees in 100 countries worldwide. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. The company's focus is on developing and marketing innovative medications for treating a variety of diseases and conditions. IMED is AstraZeneca's key business segment and encompasses the research and development of new medications. This includes innovative active substances and therapies that have the potential to fundamentally improve disease treatment. Some current research focuses include cancer therapy, immunology, respiratory diseases, and cardiovascular diseases. GPPS is responsible for the marketing and portfolio management of AstraZeneca's pharmaceuticals. This includes strategic decision-making regarding which medications should continue to be developed and brought to market. GPPS also has responsibility for the distribution channels and pricing strategy of medications, ensuring both the company's profitability and the availability of medications for patients worldwide. BioPharmaceuticals is another important business segment of AstraZeneca, focusing on the production, distribution, and marketing of medications. This primarily includes biological therapies used for the treatment of cancer, inflammatory diseases, and autoimmune diseases. Some of AstraZeneca's most well-known medications include Nexium, a treatment for gastric ulcers and heartburn; Crestor, a cholesterol-lowering drug; and Symbicort, an inhaler for the treatment of asthma and chronic bronchitis. Additionally, AstraZeneca is actively involved in developing new medications, including promising cancer therapies such as Tagrisso, Lynparza, and Imfinzi. An essential part of AstraZeneca's business model is collaboration with other companies and institutions through partnerships and cooperation. Through targeted collaborations and acquisitions, the company expands its portfolio of medications and strengthens its position in the competition. Overall, AstraZeneca's business model is focused on developing, manufacturing, and marketing innovative and effective medications to achieve improvements in patient care and treatment, thereby contributing to the well-being of society. Output: AstraZeneca PLC is a globally operating pharmaceutical company focused on research, development, and distribution of innovative medications. It was founded in 1999 and is headquartered in London, UK. The company employs over 70,000 employees in 100 countries. AstraZeneca consists of three main business segments: Innovative Medicines and Early Development (IMED), Global Product and Portfolio Strategy (GPPS), and BioPharmaceuticals. IMED focuses on research and development of new medications, while GPPS handles marketing and portfolio management. BioPharmaceuticals focuses on production, distribution, and marketing. AstraZeneca is known for medications such as Nexium, Crestor, and Symbicort. The company collaborates with other companies and institutions through partnerships and cooperation. Overall, AstraZeneca aims to develop, manufacture, and market effective medications to improve patient care and contribute to society.

odotettu liikevaihto AstraZeneca on 63,02 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto AstraZeneca on 16,01 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

AstraZeneca:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,12. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan AstraZeneca-osakkeen arvostusta.

AstraZeneca:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,09. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii AstraZeneca-osakkeen arvostuskennuslukuna.

AstraZeneca:n Eulpool-laatuscore on 8/10.

AstraZeneca:n ISIN on GB0009895292. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

AstraZeneca:n WKN on 886455. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

AstraZeneca:n ticker on AZN.L. Tämä pörssinoteeraus käytetään AstraZeneca-osakkeiden kauppaan pörssissä.